Moneyview Limited IPO
MONEYVIEW · Mainboard · 24–28 Sep 2026 · archived record
Half market demand (GMP, subscription, institutional bids), half offer-document data (valuation, profit trend, fresh issue vs OFS, debt, promoters, sector). Missing inputs are left out, not guessed. Not an apply/avoid recommendation.
120 archived readings. Marketframe stores its own observations; readings before we began archiving cannot be backfilled.
No archived readings yet. Marketframe stores a reading every 15 minutes while an issue is live.
69% of the money goes to the company; the rest goes to shareholders selling their stake.
- ₹325 Cr: funding growth of loans disbursed under default loss guarantee (DLG) deals with lending partners
- ₹250 Cr: put into its NBFC subsidiary Whizdm Finance to grow its capital base
- Up to 25%: general corporate purposes
- OFS of 10.05 crore shares goes to existing shareholders, not the company
Qualified institutional buyers are mutual funds, banks, insurers and foreign funds, and they read the full prospectus. They usually bid on the last day, so a low QIB number early in the window is normal. A low one at the close is not.
Promoter holding: Only 19.55% before the issue, fully diluted
- Total income: ₹1,389.2 Cr (FY24) → ₹2,378.5 Cr (FY25) → ₹3,404.3 Cr (FY26)
- Profit: ₹171.1 Cr → ₹240.3 Cr → ₹242.7 Cr
- Apr–Jun 2026 profit: ₹173.8 Cr, vs ₹67.2 Cr a year earlier
- Gross Stage 3 (bad) loans rose from 0.94% (Mar 2024) to 2.74% (Mar 2026)
- About 21.7× FY26 earnings at ₹34 (diluted EPS ₹1.57)
- The RHP's listed fintech/lending peers average 82× (range 17×–213×)
- About 2.2× book value (NAV ₹15.73, June 2026)
- Income grew 43% in FY26; Apr–Jun 2026 profit is 2.6× a year earlier
- Operating costs fell from 56% of income (FY24) to 35% (FY26)
- Low promoter stake (19.55%)
- Bad loans (Gross Stage 3) nearly tripled in two years
- Negative operating cash flow in FY24, FY25 and FY26
- The money raised backs loan guarantees: when borrowers default, Moneyview pays
- Unsecured personal loans are tightly regulated by the RBI
- Unsecured personal-loan platform; managed AUM ₹22,520 Cr (June 2026)
- Source: Moneyview RHP filed with NSE, September 2026
In 2 of the last 5 years, the typical Financial Services stock did better than the typical listed stock.
| Year | Typical stock | Clean average | Stocks up | Whole market | Abnormal moves set aside |
|---|---|---|---|---|---|
| 2021 | +22.6% | +28.1% | 74% of 76 | +45.5% | SHAREINDIA +482.7%, IEX +232.8% |
| 2022 | +14.1% | +21.5% | 63% of 86 | +3.0% | None |
| 2023 | +38.2% | +42.0% | 96% of 92 | +43.5% | BSE +307.6%, ANANDRATHI +269.7%, RECLTD +254.4% |
| 2024 | +11.0% | +20.0% | 64% of 98 | +23.1% | KFINTECH +218.5%, MOTILALOFS +207.5% |
| 2025 | +13.7% | +16.8% | 60% of 107 | -4.2% | None |
| 2026 YTD | -3.6% | +0.3% | 45% of 115 | -2.8% | PAISALO +112.1% |
Calendar-year returns of the Financial Services companies in the Nifty Total Market index, adjusted for splits and bonuses. The typical stock is the median, so one stock's spike or crash cannot pass for the whole sector. Moves more than three interquartile ranges from the middle are named and left out of the clean average. Only companies listed today are counted, so ones that collapsed and delisted are missing and past returns look better than they were. Past sector returns say nothing certain about this IPO.
Use NSE's official IPO bid and allotment verification page.
nseindia.comWhat is the GMP of Moneyview Limited today?
The latest unofficial grey market premium for Moneyview Limited is — (36.76% of the upper price band), sourced from InvestorGain. GMP is unofficial and unregulated.
What is the price band of Moneyview Limited?
The price band is ₹32–₹34 per share, as filed with NSE.
When does Moneyview Limited open and close?
The issue window is 24–28 Sep 2026. The current status is closed.
How much is Moneyview Limited subscribed?
Live subscription figures are published by NSE once bidding opens.
Is Moneyview Limited a good IPO to apply for?
Marketframe does not publish apply or avoid calls. The Marketframe score combines market demand (GMP, subscription, institutional bids) with facts from the offer document (valuation against listed peers, profit trend, fresh issue vs OFS, debt, promoter holding and sector record). It is an automated summary of data, not a recommendation or investment advice. Read the RHP and consult a SEBI-registered adviser.
↑Issue schedule verified from NSE
!GMP is unofficial and not verified by NSE
!Read the RHP risk factors before applying
Schedule, price band and live subscription data are sourced from NSE India. *GMP is sourced from InvestorGain, is unofficial and unregulated. The Marketframe score summarises market demand and offer-document data; it does not predict listing gains or returns. Marketframe does not provide investment advice. Verify every decision using SEBI, NSE, BSE and the relevant offer document.